Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
May 2019. 8. Proposed intervention’s place in clinical management The most recent version of the World Health Organization classification of tumours of the central nervous system defines the morphological subtypes of this group of cancers and their genetically distinct variants. By virtue of their place in the WHO Guidelines, the proposed genetic tests have documented known significance in each of the diseases specified; there are no tests proposed in the application with variations of unknown (...) with clinical or laboratory evidence, including morphological features, of glial neoplasm with probable oligodendroglial component, as requested by a specialist or consultant physician, for the detection of chromosome 1p/19q co-deletion. Maximum one test per lifetime Fee: $340 XXXXX-09 Analysis of tumour tissue from a patient with clinical or laboratory evidence, including morphological features, of glial neoplasm, as requested by a specialist or consultant physician, for the identification of IDH1/2
edition) 2018. Elsevier. ISBN978-0-323-52357-8 9 Jacob, J et al. Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base. Journal of surgical Oncology. 2016; 113(7): 721-5 11 rearranged, which confers a worse prognosis, is 1%. 10 However, the applicant states that approximately 10% of the incident population would require the proposed test. Table 3: Estimated disease incidence and number of tests to be performed annually Genetic test(s) Tumour type Estimated number (...) , and gene mutations which develop in cells after the egg is fertilised are called “somatic mutations”. Somatic tumour testing is where a piece of a tumour is tested to look at the somatic mutations in the cancer cells. These tests can help provide patients with appropriate, targeted treatment, or advice about the outcome of their disease. Applications 1526, 1527 and 1528 are for somatic tumour testing for rare cancers. They have been grouped together because the numbers of patients with each
intervention’s place in clinical management The most recent version of the World Health Organization classification of lymphoid neoplasms defines the morphological subtypes of this group of cancers and their genetically distinct variants. By virtue of their place in the WHO Guidelines, the proposed genetic tests have documented known significance in each of the diseases specified; there are no tests proposed in the application with variations of unknown significance. The clinical utility of each test (...) spanned three applications: • Application No. 1526 – Somatic gene testing of haematological malignancies • Application No. 1527 – Somatic gene testing of central nervous system tumours and sarcomas • Application No. 1528 – Somatic gene testing of hydatidiform mole, granulosa cell tumour of the ovary, midline squamous cell carcinoma, salivary gland carcinoma, secretory carcinoma of the breast and renal cell carcinoma. 4 MSAC noted that there has been a long history of meetings for these applications
MBS items to cover the urological component and radiation oncology component of LDR-BT for use as a boost to EBRT in patients with high- intermediate and high-risk prostate cancer. The proposed MBS item descriptors are summarised in Table 1. 4 Table 1 Applicant proposed MBS item descriptor Category 3 – Therapeutic procedures PROSTATE, radioactive seed implantation (radiation oncology component), using transrectal ultrasound guidance, for localised (non-metastatic) prostatic malignancy classified (...) (urological component), using transrectal ultrasound guidance, for localised (non-metastatic) prostatic malignancy classified as high-intermediate risk (defined as having a prostate specific antigen (PSA) of 10-20 ng/ml and a Gleason score of 7 and a tumour classified as T2b-c) or high risk (defined as having a PSA of greater than 20 ng/ml and/or a Gleason score of 8-10 and/or a tumour classified as T3). It is recommended the procedure only be performed as ‘boost’ treatment, in addition to external beam
: about 60% of NSCLCs are adenocarcinoma. Former or current smoking is often a causal factor in all forms of lung cancer. However, nonsmokers with lung cancer frequently have adenocarcinoma. This type of cancer is usually found on the outer parts of the lung. People with adenocarcinoma tend to have better survival than people with other types of lung cancer • Squamous cell (epidermoid) carcinoma: 25% to 30% of all NSCLCs are squamous cell carcinomas. Squamous cells are flat cells that line the inside (...) • Other subtypes: Less common NSCLC subtypes include adenosquamous carcinoma and sarcomatoid carcinoma The progression of cancer is divided into four stages; a higher number signifies more extensive disease. In stage 1, the cancer is confined to the original site within the lung and there is no sign of spread to lymph nodes (N0) or elsewhere (M0). In stage 2, the cancer has spread to lymph nodes within the lung (N1). In stage 3, the cancer has spread to lymph nodes in the middle of the chest
-expression-profiling-tests-for-early-stage-invasive-breast-cancer March 2020 Ontario Health Technology Assessment Series; Vol. 20: No. 10, pp. 1–234, March 2020 3 ABSTRACT Background Breast cancer is a disease in which cells in the breast grow out of control. They often form a tumour that may be seen on an x-ray or felt as a lump. Gene expression profiling (GEP) tests are intended to help predict the risk of metastasis (spread of the cancer to other parts of the body) and to identify people who will most (...) and the experiences, preferences, and values of people with early-stage invasive breast cancer. BACKGROUND Health Condition Breast cancer is a disease in which cells in the breast grow out of control, eventually forming a tumour. Environmental, lifestyle, and genetic factors influence a person’s risk of developing breast cancer. These risk factors may include obesity, physical inactivity, alcohol consumption, age, hormone replacement therapy, dense breasts, genetic mutation, and a personal and/or family history
Cinacalcet hydrochloride (Mimpara) - Secondary hyperparathyroidism (HPT) or Parathyroid carcinoma and primary HPT in adults Published 9 March 2020 www.scottishmedicines.org.uk Statement of advice SMC2275 cinacalcet hydrochloride 1mg, 2.5mg and 5mg granules in capsules for opening (Mimpara®) Amgen Ltd 7 February 2020 Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium (...) or carer. Vice Chairman Scottish Medicines Consortium ADVICE: in the absence of a submission from the holder of the marketing authorisation cinacalcet hydrochloride granules in capsules for opening (Mimpara®) is not recommended for use within NHSScotland. Indication under review: Secondary hyperparathyroidism (HPT) ? Treatment of secondary HPT in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. ? Treatment of secondary HPT in children aged 3 years and older with ESRD
(Lorviqua ® ) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI In the relevant subgroup of a non-comparative (...) Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: 1 ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI Dosing Information The recommended dose is 100mg lorlatinib taken orally once daily. Treatment with lorlatinib
the penultimate dose) and had received at least two prior platinum-based chemotherapy regimens. Response to chemotherapy could be either complete or partial as defined by Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 or a serological response according to Gynaecologic Cancer InterGroup (GCIG) cancer antigen 125 (CA 125) criteria. There was no restriction on residual carcinoma size for those defined as having a partial response. Patients who had persistent lesions of >2cm were defined (...) The recommended dose is 600mg twice daily, equivalent to a total daily dose of 1200mg, until disease progression or unacceptable toxicity. For the maintenance treatment, patients should start the maintenance treatment with rucaparib no later than eight weeks after completion of their final dose of platinum containing regimen. There is no requirement for BRCA testing prior to using rucaparib for the maintenance treatment of adult patients with relapsed high-grade epithelial ovarian cancer, fallopian tube
because of palliative treatment and new biological treatments for advanced disease. BetterunderstandingofthenaturalhistoryofGIcancershas shown that most of them are preceded by slowly progressing precancerous conditions or lesions, as well as by early invasive stages, therefore providing opportunities for effective inter- ventions. Beyond the classic adenoma–carcinoma sequence for colorectal carcinogenesis, similar pathways based on metaplasia–dysplasia–cancer progression have been shown for upper GI (...) ,colorectalcancer,andpancreaticcancer)werecon- sidered. 3 For esophageal and pancreatic cancer, endoscopic screening may be considered only in high-risk individuals: – For squamous cell carcinoma, in those with a personal history of head/neck cancer, achalasia, or previous caustic injury; – For Barrett’s esophagus (BE)-associated adenocarci- noma,inthosewithlong-standinggastroesophagealreflux disease symptoms (i.e.,>5 years) and multiple risk factors (age=50 years, white race, male sex, obesity, first-degree
cell carcinoma a The following Table replaces Table 7. Therapy Pembrolizumab in combination with axitinib Disease setting Previously untreated advanced renal cell carcinoma Trial Study to evaluate the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib monotherapy in participants with renal cell carcinoma (KEYNOTE-426)  NCT02853331 Phase Phase III Control Sunitinib PFS 11.1 months 12 months survival 78% Absolute survival gain PFS gain 4 months 12 months survival (...) gain: 12% HR (95% CI) PFS HR 0.69 (0.57-0.84) OS HR: 0.53 (0.38-0.74) c significant QoL/toxicity - ESMO-MCBS score b 4 (Form 2b) Therapy Nivolumab, a PD-1 checkpoint inhibitor Disease setting Advanced clear cell renal cell carcinoma previously treated with one or two regimens of anti-angiogenic therapy Trial Study of nivolumab vs. everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma (CheckMate 025)  NCT01668784 Phase Phase III Control Everolimus Median OS: 19.6 months
, Marco Cura, MD, Ahmed Kamel Abdel Aal, MD, PhD, Jason W. Mitchell, MD, MPH, MBA, Sreekumar Madassery, MD, Sasan Partovi, MD, Timothy D. McClure, MD, Alda L. Tam, MD, MBA, and Sheena Patel, MPH ABBREVIATIONS AUA¼ American Urological Association, CI¼ con?dence interval, CSS¼ cancer-speci?c survival, EAU¼ European Association of Urology, HR ¼ hazard ratio, MW ¼ microwave, NCCN ¼ National Comprehensive Cancer Network, PA ¼ percutaneous ablation, PN ¼ partial nephrectomy, RCC ¼ renal cell carcinoma, RCT (...) ¼ randomized controlled trial, RF ¼ radiofrequency, RN ¼ radical nephrectomy, SEER¼ Survival, Epidemiology, and End Results, WMD¼ weighted mean difference BACKGROUND It is estimated that, in 2019, 73,820 new cases of kidney cancer will be diagnosedintheUnitedStates,resultingin14,770newdeaths(1).Renalcell carcinoma(RCC)isthemostcommontypeofkidneycancer,accountingfor approximately9outof10kidneycancers(2).Owingtotheincreasinguseof cross-sectionalimagingandimprovinglifeexpectancies,theincidencerates
Shared follow-up and survivorship care for low-risk endometrial cancer: A guide for women canceraustralia.gov.au SHARED FOLLOW-UP AND SURVIVORSHIP CARE FOR LOW-RISK ENDOMETRIAL CANCER A guide for women on shared follow-up and survivorship care Why is follow-up and survivorship care important? After treatment for low-risk endometrial cancer, it is important to have follow-up visits to: check whether the cancer has come back monitor and address any side effects of treatment receive practical (...) and emotional support. Follow-up care involves your primary care team (General Practitioner (GP) and primary health care nurse) and the specialist multidisciplinary gynaecological cancer team (specialist team). What is shared follow-up and survivorship care? When your follow-up care is shared between your specialist team and your primary care team, this is known as shared follow-up and survivorship care. Allied health professionals, such as dietitians, psychologists and others, may also be involved in your
Shared follow-up and survivorship care for low-risk endometrial cancer: Roles and responsibilities for the delivery of care canceraustralia.gov.au Roles and Responsibilities for the delivery of care This resource is for all members of the multidisciplinary team. It provides an overview of key roles and responsibilities of the specialist multidisciplinary gynaecological cancer team (specialist team) and primary care team in the commencement and delivery of shared follow-up care for low-risk (...) endometrial cancer. Shared follow-up and survivorship care for low-risk endometrial cancer is designed for women who have completed active treatment for low-risk endometrial cancer. Shared care involves the joint participation of primary and specialist teams in the planned delivery of patient care. Shared care can provide women with the benefits of care by a specialist team combined with continuity of care and ongoing management from primary care providers. Establishing agreed shared care arrangements
-morbidities Many women with endometrial cancer also experience a range of co-morbidities including: obesity related issues hypertension diabetes cardiovascular disease* Co-morbidities increase the complexity of follow-up care for women with low-risk endometrial cancer and their care should be managed holistically using a multidisciplinary approach. Addressing the underlying risk factors for these conditions has the potential to improve outcomes of women affected by low-risk endometrial cancer 3 (...) . Screening, assessing and managing the effects of treatment, co-morbidities and secondary prevention are important aspects of a holistic and multidisciplinary approach to managing follow-up care for women with low-risk endometrial cancer. Referral to appropriate health providers is required to meet the identified needs of the woman, her carer and family. SHARED FOLLOW-UP AND SURVIVORSHIP CARE FOR LOW-RISK ENDOMETRIAL CANCER * Evidence suggests that cardiovascular disease is the leading cause of death
or depressed changes in memory, attention and concentration fin ancial or employment issues (such as loss of income or costs of treatment, travel and accommodation) lower leg lymphoedema (swelling of the legs) which can affect mobility (unlikely following treatment for low-risk endometrial cancer). What can I do to live well after endometrial cancer? There are a number of other medical issues or diseases that can occur alongside endometrial cancer. These are known as co-morbidities and they may impact (...) on your wellbeing after endometrial cancer. Being overweight or obese is a common co-morbidity among people with endometrial cancer. Diabetes, cardiovascular disease and high blood pressure are some other common co-morbidities. Managing co-morbidities has the potential to improve your health and wellbeing following treatment for endometrial cancer. If you experience any side effects, including ones that are not listed here, it is important that you speak with your primary care team (General
Plerixafor (Mozobil) - lymphoma or solid malignanttumours Final Appraisal Recommendation Advice No: 0120 – February 2020 Plerixafor (Mozobil ® ) 20 mg/ml solution for injection Limited submission by Sanofi Aventis Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. • AWMSG considered plerixafor (Mozobil ® ) as an ultra-orphan medicine according to the criteria in the AWMSG appraisal process for a medicine for a rare disease (...) and will be considered for review every three years. Recommendation of AWMSG Plerixafor (Mozobil ® ) is recommended for use within NHS Wales in combination with granulocyte colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged = 1 to <18 years with lymphoma or solid malignanttumours either: • pre-emptively, when circulating stem cell count on the predicted day of collection after
Oncol. 2016;6:31. Fung Kee Fung M, Dodge J, Elit L et al. on behalf of the Cancer Care Ontario Program in Evidence-based Care Gynecology CancerDisease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 2006;101:520–9. Nowak R, Bi J, Koohestani F et al. Female Reproductive C: Uterine Tumors and the Environment. Comprehensive Toxicology. 2018;438–69. Sartori E, Pasinetti B, Chiudinelli F et al. Surveillance procedures for patients treated (...) and survivorship care for women with low-risk endometrial cancer. References: 1. Cancer Australia. Follow-up care for women with low-risk endometrial cancer: A guide for General Practitioners. Surry Hills, NSW: Cancer Australia; 2019. 2. Smith SM, Allwright S, T. OD. Effectiveness of shared care across the interface between primary and specialty care in chronic disease management. Cochrane Database Syst Rev. 2007;18(3). The definition of ‘low-risk endometrial cancer’ may vary from one specialist gynaecological